{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:49:39Z","timestamp":1791823779816,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-05116-6","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:33:33Z","timestamp":1784201613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatic and splenic tuberculosis following infliximab therapy for refractory ulcerative colitis: a case report and literature review"],"prefix":"10.1186","volume":"26","author":[{"given":"Shuo","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"1","key":"5116_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"R Tim","year":"2022","unstructured":"Tim R, Stefanos B, Johan B, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2\u201317.","journal-title":"J Crohns Colitis"},{"key":"5116_CR2","unstructured":"Keane J, Gershon S, Wise RP, Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med., Anna K, Katarzyna GC et al. S, Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents. Int J Inflam. 2021 Jan 5:2021:6284987."},{"key":"5116_CR3","doi-asserted-by":"crossref","unstructured":"Adam K, Anna GC, Katarzyna S, et al. Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents. Int J Inflam. 2021 Jan 5:2021:6284987.","DOI":"10.1155\/2021\/6284987"},{"key":"5116_CR4","unstructured":"Min JK, Kim YJ, Daehyun J et al. Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-\u03b1 agents: a nationwide population-based cohort study. Th Adv Gastroenterol 2024 Jul 31:1717562848241265013."},{"key":"5116_CR5","unstructured":"Matheus FCA, Lu\u00edsa LB, Filipe FJ et al. Active tuberculosis in inflammatory bowel disease patients: a case-control study. Th Adv Gastroenterol 2023 Jul 4:1617562848231179871."},{"issue":"3","key":"5116_CR6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.14309\/ajg.0000000000000527","volume":"115","author":"K Saurabh","year":"2020","unstructured":"Saurabh K, Venigalla PM, Nagesh K, et al. Risk of tuberculosis in patients with inflammatory bowel disease on infliximab or adalimumab is dependent on the local disease burden of tuberculosis: a systematic review and meta-analysis. Am J Gastroenterol. 2020;115(3):340\u20139.","journal-title":"Am J Gastroenterol"},{"key":"5116_CR7","doi-asserted-by":"crossref","unstructured":"Lu\u00edsa LB, Alexandre dSC, Matheus FCA. An unusual presentation of tuberculosis in a Crohn\u2019s disease patient treated with anti-TNF. Gastro Hep Adv. 2022;1(5):792\u20133.","DOI":"10.1016\/j.gastha.2022.05.001"},{"key":"5116_CR8","doi-asserted-by":"crossref","unstructured":"Alexander PA, James YH, Fady AY. Intestinal Tuberculosis Masquerading as Crohn\u2019s Disease? A Case of Disseminated Tuberculosis after Anti-TNF Therapy for Suspected Crohn\u2019s Disease. Case Rep Gastrointest Med. 2019 Dec;14:20196053503.","DOI":"10.1155\/2019\/6053503"},{"issue":"4","key":"5116_CR9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s40257-019-00432-y","volume":"20","author":"S Igor","year":"2019","unstructured":"Igor S, Einav B, Efrat SC, et al. Active tuberculosis in patients with psoriasis receiving biologic therapy: a systematic review. Am J Clin Dermatol. 2019;20(4):483\u201391.","journal-title":"Am J Clin Dermatol"},{"key":"5116_CR10","doi-asserted-by":"crossref","unstructured":"Bruce ES, Laurent PB, Edward VL, Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med., Iba H et al. A, TomioJ. Treatment of latent tuberculosis infection in patients receiving biologic agents. J. Infect. Chemother. 2021, 27, 243\u2013249.","DOI":"10.1016\/j.jiac.2020.09.028"},{"key":"5116_CR11","doi-asserted-by":"crossref","unstructured":"Yamana H, Iba A, TomioJ.et al. Treatment of latent tuberculosis infection in patients receiving biologic agents. J. Infect. Chemother. 2021, 27, 243-249.","DOI":"10.1016\/j.jiac.2020.09.028"},{"key":"5116_CR12","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3109\/07853890.2014.941919","volume":"46","author":"R Lorenzetti","year":"2014","unstructured":"Lorenzetti R, Zullo A, Ridola L, et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: A systematic review of randomized controlled trials. Ann Med. 2014;46:547\u201354.","journal-title":"Ann Med"},{"issue":"14","key":"5116_CR13","doi-asserted-by":"publisher","first-page":"4990","DOI":"10.3390\/jcm14144990","volume":"14","author":"AMM Jos\u00e9","year":"2025","unstructured":"Jos\u00e9 AMM, Marisol A, Ana Luz CD, et al. Prevalence and Risk Factors of Latent Tuberculosis Infection Detected by IGRA in Patients with Immune-Mediated Inflammatory Diseases Before and During Biologic DMARD Therapy (TITAN Study). J Clin Med. 2025;14(14):4990.","journal-title":"J Clin Med"},{"issue":"11","key":"5116_CR14","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1111\/apt.16936","volume":"55","author":"SF Adam","year":"2022","unstructured":"Adam SF, Jordan EA. Editorial: safety in numbers - cycling of biologics does not increase risk of adverse outcomes. Aliment Pharmacol Ther. 2022;55(11):1459\u201360.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"5116_CR15","doi-asserted-by":"publisher","first-page":"e2022063","DOI":"10.4084\/MJHID.2022.063","volume":"14","author":"L Saiduo","year":"2022","unstructured":"Saiduo L, Wei C, Shi J, et al. Clinical Manifestation, Imaging Features and Treatment Follow-up of 29 Cases with Hepatic Tubercolosis. Mediterr J Hematol Infect Dis. 2022;14(1):e2022063.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"9","key":"5116_CR16","first-page":"845","volume":"6","author":"Z Wu","year":"2013","unstructured":"Wu Z, Wang WL, Zhu Y, et al. Diagnosis and treatment of hepatic tuberculosis: report of five cases and review of literature. Int J Clin Exp Med. 2013;6(9):845\u201350.","journal-title":"Int J Clin Exp Med"},{"issue":"6","key":"5116_CR17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s13244-015-0440-y","volume":"6","author":"K Chandan","year":"2015","unstructured":"Chandan K, Ashwin MP, Prakashini K, et al. Hepatic tuberculosis: a multimodality imaging review. Insights Imaging. 2015;6(6):647\u201358.","journal-title":"Insights Imaging"},{"key":"5116_CR18","doi-asserted-by":"publisher","unstructured":"Ziganshina LE, Titarenko AF, Davies GR. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). Cochrane Database Syst Rev. 2013;6CD004795. https:\/\/doi.org\/10.1002\/14651858.cd004795.pub4.","DOI":"10.1002\/14651858.cd004795.pub4"},{"key":"5116_CR19","doi-asserted-by":"crossref","unstructured":"MasoodMuaaz. et al, et al. P040\u2003Latent Tuberculosis Infection In A Patient With A Negative Interferon Gamma Release Assay Prior to Biologic Initiation for Crohn\u2019s Disease. The American journal of gastroenterology; 2021.","DOI":"10.14309\/01.ajg.0000798760.44348.35"},{"key":"5116_CR20","unstructured":"F\u00e9licie C et al. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-\u03b3 release assay results. J Rhuematol. 2013."},{"key":"5116_CR21","unstructured":"Carolina MG, et al. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida. International journal of dermatology; 2015."},{"key":"5116_CR22","volume-title":"Module 2: Screening \u2013 systematic screening for tuberculosis disease","author":"WHO consolidated guidelines on tuberculosis","year":"2021","unstructured":"WHO consolidated guidelines on tuberculosis. Module 2: Screening \u2013 systematic screening for tuberculosis disease. Geneva: World Health Organization; 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240022676."},{"key":"5116_CR23","doi-asserted-by":"crossref","unstructured":"Wang HF, Huang YQ, Feng J, et al. Hepatic tuberculosis induced by rituximab treatment for C1q nephropathy with minimal change disease: a case report. Frontiers in medicine. Front Med (Lausanne). 2025 Aug;29:121621723.","DOI":"10.3389\/fmed.2025.1621723"},{"key":"5116_CR24","doi-asserted-by":"crossref","unstructured":"Li L, Zhang J, Song Q, et al. Diagnosis of isolated hepatic tuberculosis in an immunocompetent individual: a case report and review of misdiagnosed cases. Front Med (Lausanne). 2025 Nov;14:121687127.","DOI":"10.3389\/fmed.2025.1687127"},{"issue":"1","key":"5116_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4269\/ajtmh.20-0023","volume":"104","author":"C Ruxandra","year":"2021","unstructured":"Ruxandra C, Anna B, Pauline C, et al. Abdominal tuberculosis: experience from two tertiary-care hospitals in the Paris region. Am J Trop Med Hyg. 2021;104(1):223\u20138.","journal-title":"Am J Trop Med Hyg"},{"key":"5116_CR26","unstructured":"Chien K, Seemangal J, Batt J Abdominal tuberculosis: a descriptive case series of the experience in a Canadian tuberculosis clinic. Int J Tuberc Lung Dis., Udhaya L, Anirban GM, Evan PS et al. Protective role of coenzyme Q10 against isoniazid and rifampicin-induced hepatotoxicity in rats via modulation of PPAR-\u03b3, iNOS, and NF-\u03baB. J Biochem Mol Toxicol. 2025;39(11):e70585."},{"key":"5116_CR27","doi-asserted-by":"crossref","unstructured":"Udhaya L, Anirban GM, Evan PS, et al. Protective role of coenzyme Q10 against isoniazid and rifampicin-induced hepatotoxicity in rats via modulation of PPAR-\u03b3, iNOS, and NF-\u03baB. J Biochem Mol Toxicol. 2025 Nov;39(11):e70585.","DOI":"10.1002\/jbt.70585"},{"key":"5116_CR28","doi-asserted-by":"crossref","unstructured":"Sun Y, Zhang Y, Ma N et al. Rhus chinensis Mill. fruits alleviate liver injury induced by isoniazid and rifampicin through regulating oxidative stress, apoptosis, and bile acid transport. J Ethnopharmacol 2023 Jun 28:310116387.","DOI":"10.2139\/ssrn.4149292"},{"key":"5116_CR29","doi-asserted-by":"crossref","unstructured":"Atieh Y, Javid D, Fereshteh A, et al. Therapeutic effect of an anti-tuberculosis agent, isoniazid, and its nano-isoform in ulcerative colitis. Int Immunopharmacol. 2021 Jul;96:107577.","DOI":"10.1016\/j.intimp.2021.107577"},{"issue":"3","key":"5116_CR30","doi-asserted-by":"publisher","first-page":"jjaf032","DOI":"10.1093\/ecco-jcc\/jjaf032","volume":"19","author":"S Matthew","year":"2025","unstructured":"Matthew S, Keith K, Simon R, et al. Uncovering the therapeutic potential of anti-tuberculoid agent Isoniazid in a model of microbial-driven Crohn\u2019s disease. J Crohns Colitis. 2025;19(3):jjaf032.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"5116_CR31","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","volume":"158","author":"JS William","year":"2020","unstructured":"William JS, Filip B, Silvio D, et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):562\u2013e57212.","journal-title":"Gastroenterology"},{"key":"5116_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.07.038","author":"N Narula","year":"2021","unstructured":"Narula N, Wong E, Marshall J, et al. Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis. Clinical gastroenterology and hepatology: the official clinical practice. J Am Gastroenterological Association. 2021. https:\/\/doi.org\/10.1016\/j.cgh.2021.07.038.","journal-title":"J Am Gastroenterological Association"},{"key":"5116_CR33","doi-asserted-by":"publisher","unstructured":"Emily CLW, Emily CLW, Vipul J et al. Infliximab and upadacitinib demonstrate superior early onset of efficacy in biologic-na\u00efve ulcerative colitis with severe endoscopic disease. Am J Gastroenterol,2026. https:\/\/doi.org\/10.14309\/ajg.0000000000003940.","DOI":"10.14309\/ajg.0000000000003940"},{"issue":"10341","key":"5116_CR34","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"D Silvio","year":"2022","unstructured":"Silvio D, S\u00e9verine V, Wen Z, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113\u201328.","journal-title":"Lancet"},{"issue":"1","key":"5116_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/ibd\/izad032","volume":"30","author":"RB Liu","year":"2024","unstructured":"Liu RB, Li ZL, Ye LG, et al. Risk of tuberculosis and hepatitis B reactivation in patients with Crohn\u2019s disease on Ustekinumab: a nationwide real-world study. Inflamm Bowel Dis. 2024;30(1):45\u201352.","journal-title":"Inflamm Bowel Dis"},{"key":"5116_CR36","unstructured":"David TR, Jessica RA, Juli\u00e1n P et al. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet 2025 Jan 4;405(10472):33\u201349."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05116-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05116-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05116-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:06:18Z","timestamp":1791821178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-05116-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5116"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-05116-6","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in this study involving human participants were in accordance with the 1964 Helsinki Declaration and subsequent relevant ethics. Written informed consent was obtained from the patient this Case Report and any accompanying images.Written informed consent was obtained from the patient for participation in this case report and the publication of related clinical data, imaging images and relevant medical records. The patient fully understood the purpose, content and form of publication and agreed to the anonymous use of their clinical information without any personal identifiable information disclosed.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"637"}}